Literature DB >> 3394686

Colorectal cancer location and synchronous adenomas.

G Slater1, P Fleshner, A H Aufses.   

Abstract

In this study, the relationship between the location of colorectal cancer and synchronous benign adenomas was assessed in 591 patients. Adenomas were found in 29.7% of all patients. Patients with cancer of the cecum, ascending colon, and hepatic flexure had the highest percentage of benign adenomas. Patients with right-sided cancer had adenomas in 47% of resected specimens, which percentage was significantly higher than that in the group of patients with left-sided cancer, who had adenomas in 22% of their specimens (p less than 0.001). Patients with cancer and synchronous adenomas were also older (70.2 vs 67.8, p less than 0.02) and more likely to be male (p less than 0.002) than patients with cancer and no adenomas. It is suggested that efforts be made to identify adenomas preoperatively in patients with colorectal cancer. In addition, since patients with cancer and associated adenomas are at increased risk of developing metachronous cancer, the group with right-sided cancer should be part of a particularly active surveillance program.

Entities:  

Mesh:

Year:  1988        PMID: 3394686

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

1.  Clustering of colorectal neoplasia: characteristics of coexisting adenomas in patients with severely dysplastic polyps or invasive (malignant) polyps as compared to patients with benign adenomas or carcinomas.

Authors:  A Pines; L Bat; E Shemesh; J Rosenblum; A Horowitz; Y Levo; J J Bubis
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Risk factors for metachronous adenoma in the residual colon of patients undergoing curative surgery for colorectal cancer.

Authors:  Abhilasha Patel; Nigel Williams; Nicholas Parsons; Omar Ali; Francesca Peters; Reesha Ranat; Jasmine Shah; Emma Spector; Ramesh P Arasaradnam
Journal:  Int J Colorectal Dis       Date:  2017-08-21       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.